SuperGen, Inc. to Change Name and Stock Ticker Symbol

SuperGen, Inc. (NASDAQ: SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, announced it anticipates that it will begin operating under the name Astex Pharmaceuticals, Inc. on September 12, 2011. The new name follows the previously announced closing of its acquisition of Astex Therapeutics Limited, a privately held, UK-based biotechnology company developing targeted therapies. Astex Pharmaceuticals, Inc. is expected to begin trading on NASDAQ under the symbol ASTX on September 12, 2011.

Astex Therapeutics Limited became a wholly owned subsidiary of SuperGen, Inc. on July 20, 2011. Further information about this transaction is available at http://www.astex-supergen.com, or in the investor relations section of the SuperGen website at http://www.supergen.com.

About SuperGen

SuperGen is a pharmaceutical company dedicated to the discovery and development of novel cancer therapeutics in epigenetic and cell signaling modulation. The Company develops products through biochemical and clinical proof of concept to partner for further development and commercialization. SuperGen developed Dacogen® and receives significant royalties on global sales.

For more information about SuperGen, please visit http://www.supergen.com.

Note on Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including but not limited to, statements regarding the expectation that the Company will change its name and ticker symbol. These and other forward-looking statements involve certain risks and uncertainties that could cause actual results to differ materially from those indicated in such forward-looking statements, including, but not limited to, the ability of the Company to change its name and its ticker symbol, and such other risks as identified in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2010, and the Company’s most recent Quarterly Reports on Form 10-Q, each as filed with the SEC, which contain and identify important factors that could cause the actual results to differ materially from those contained in the forward-looking statements. The Company assumes no obligation to update any forward-looking statement contained in this press release.